Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRIDA: Reparixin + Paclitaxel in Metastatic TNBC
NCT02370238Phase 2Completed
- Sponsor
- Dompé
- Start
- Jul 2015
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in triple-negative breast cancer (TNBC) comparing Paclitaxel + Reparixin with Paclitaxel + Placebo (2 arms). Primary endpoint: Progression-Free Survival up to 721 days. Started Jul 2015; status: completed.
02
Drugs
reparixin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02370238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02370238.